Lead‑Plaintiff Deadline Set in Soleno Securities Suit Over DCCR Disclosures

Overview

• The putative class action, City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26‑cv‑01979, is filed in the Northern District of California.
• Plaintiffs allege Soleno misrepresented or concealed safety signals in the Phase 3 program for DCCR, including excess fluid retention, which they say reduced the drug’s commercial viability.
• Soleno’s September 10, 2025 Form 8‑K disclosed a patient death after taking DCCR, and the stock fell about 19% over the next two trading days.
• Catalysts cited include Scorpion Capital’s August 15, 2025 report alleging safety and data issues (~12% decline) and Soleno’s November 4, 2025 results noting DCCR launch disruption with fewer start forms and more discontinuations (~26–27% decline on November 5).
• Multiple law firms are notifying investors of a March 26–November 4, 2025 class period and urging motions for lead‑plaintiff appointment by May 5, 2026.